Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein loss in urine predicts effectiveness of hypertension medication

08.02.2008
People with albuminuria, increased protein loss in the urine, have an increased risk of kidney and cardiovascular diseases.

Cornelis Boersma, pharmacist and PhD student at the University of Groningen, has analysed the medical data of over 8,500 Groningers and discovered that preventive measures work better if the amount of protein loss is higher. This has important consequences for future prevention programmes. The results of this research were published on 30 January 2008 in the British Journal of Clinical Pharmacology.

The kidneys filter urea from the blood. This occurs in the millions of capillaries (very thin blood vessels) which make up a kidney. If the filtering does not work properly, protein is released into the urine – an indication that the capillaries are not functioning properly. At the same time, this can be a sign that the rest of the blood vessels in the body are not functioning properly either.

PREVEND study
The PREVEND study was set up in order to investigate whether people with protein loss in the urine have an increased risk of kidney and cardiovascular diseases (PREVEND = Prevention of REnal and Vascular ENd-stage Disease). To this end, over 8,500 Groningers submitted urine in 1997 and the protein levels in these samples were carefully measured in the laboratory. The Groningers were then tracked for years, particularly concerning their medicine use and the occurrence of cardiovascular disease.
ACE inhibitor
A recent analysis of the Groningen data by Cornelis Boersma has revealed that people with high blood pressure only have an increased risk of cardiovascular disease if they also have protein loss in the urine. What is more important is the discovery that the effectiveness of antihypertensives depends on the level of protein loss in the urine: the greater the protein loss, the more effective the hypertension medications are against cardiovascular disease. A GP has to treat 111 people with hypertension in order to prevent 1 instance of stroke or heart attack if there is no protein loss, but only 8 if there is protein loss. In addition, these new data suggest that – if you want to prevent cardiovascular disease – the best medication for people with more protein loss is perhaps a so-called ACE inhibitor (a specific antihypertensive).
Screening
These results will have important consequences for any large-scale prevention programme: by screening for albuminuria, people with hypertension, and thus a greater risk of cardiovascular disease, can be more quickly identified. In addition, it is now possible to determine which people can best be prescribed antihypertensives. In such a prevention programme, for example, people's urine could be tested in a laboratory once every four years and when anomalous values are discovered medication can be prescribed. The researchers now want to investigate which would be the most beneficial and cost-effective screening programme for which groups of people.

Communication Office | alfa
Further information:
http://www.prevend.org/Userfiles/109Boersma.pdf
http://www.rug.nl/Corporate/nieuws/archief/archief2008/persberichten/015_08

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>